Program
imeglimin
Also written as “Imeglimin” and “Imeglimin Hydrochloride Film Coated Tablet”.
Its studies are mostly in Diabetes Mellitus, Type 2, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Poxel | 60 open or running | phase 2since Sep 19, 2013 | Sep 19, 2013 | none ahead |
| Humanis Saglık Anonim Sirketi | 10 open or running | phase 1since Jul 1, 2026 | Jul 1, 2026 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 19, 2013First study: phase 2 study in Diabetes Mellitus, Type 2New to PoxelPoxel · NCT01951235 · 315 enrolled · Latvia
- Feb 2, 2015Phase 1 study in Diabetes Mellitus, Type 2Poxel · NCT02373150 · 48 enrolled · United Kingdom
- Oct 4, 2016Phase 1 study in Qt Interval, Variation inPoxel · NCT02924337 · 55 enrolled · United Kingdom
- Jun 8, 2018Phase 1 study in HealthyPoxel · NCT03618316 · 16 enrolled · United Kingdom
- Aug 23, 2018Phase 1 study in BioequivalencePoxel · NCT03646331 · 16 enrolled · United Kingdom
- Jan 10, 2019Phase 1 study in Hepatic ImpairmentPoxel · NCT03802786 · 14 enrolled · Germany
- Jul 1, 2026Humanis Saglık Anonim Sirketi's first study: phase 1 study in Diabetes Mellitus, Type 2New to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT07691177 · 40 enrolled · India
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07691177Diabetes Mellitus, Type 2 · India | 1 | Completed | Humanis Saglık Anonim Sirketi | Mar 27, 2026 | 40 |
| NCT03802786Hepatic Impairment · Germany | 1 | Completed | Poxel | Jul 3, 2019 | 14 |
| NCT03646331Bioequivalence · United Kingdom | 1 | Completed | Poxel | Sep 27, 2018 | 16 |
| NCT03618316Healthy · United Kingdom | 1 | Completed | Poxel | Jul 21, 2018 | 16 |
| NCT02924337Qt Interval, Variation in · United Kingdom | 1 | Completed | Poxel | Dec 2016 | 55 |
| NCT02373150Diabetes Mellitus, Type 2 · United Kingdom | 1 | Completed | Poxel | Oct 2015 | 48 |
| NCT01951235Diabetes Mellitus, Type 2 · Latvia | 2 | Completed | Poxel | Jul 2014 | 315 |
How it is read
Names in the registry
- “Imeglimin”, 6 entries
- “Imeglimin Hydrochloride Film Coated Tablet”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.